(Q38211342)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Thyroid dysfunctions induced by tyrosine kinase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Silvia M Ferrari

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Andrea Di Domenicantonio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Alda Corrado

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Salvatore Benvenga

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Alessandro Antonelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

English

0 references

publication date

12 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

723-733

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sorafenib: from literature to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Vandetanib for the treatment of medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Medical therapies for hepatocellular carcinoma: a critical view of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Dedifferentiated thyroid cancer: a therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sorafenib and thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Effect of sunitinib on growth and function of FRTL-5 thyroid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sunitinib induces hypothyroidism with a markedly reduced vascularity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

RET TKI: potential role in thyroid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

New targeted therapies for thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Imatinib induces hypothyroidism in patients receiving levothyroxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Vandetanib for the treatment of thyroid cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Axitinib for the treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Motesanib and advanced NSCLC: experiences and expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

New targeted therapies for anaplastic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Motesanib diphosphate in progressive differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Case of sorafenib-induced thyroid storm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

Unanswered questions regarding the management of sunitinib-induced hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.913021

10.1517/14740338.2014.913021

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24821006%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference